Last reviewed · How we verify
stable erythropoietin therapy
stable erythropoietin therapy is a erythropoiesis-stimulating agent Small molecule drug developed by American Regent, Inc.. It is currently in Phase 3 development for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy.
Stable erythropoietin therapy works by stimulating the production of red blood cells.
Stable erythropoietin therapy works by stimulating the production of red blood cells. Used for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy.
At a glance
| Generic name | stable erythropoietin therapy |
|---|---|
| Sponsor | American Regent, Inc. |
| Drug class | erythropoiesis-stimulating agent |
| Target | erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Erythropoietin is a hormone that promotes the formation of red blood cells in the bone marrow. By providing a stable form of erythropoietin, this therapy helps to increase red blood cell production, which can help to alleviate anemia in patients with chronic kidney disease or other conditions.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia associated with chemotherapy
Common side effects
- Increased risk of thromboembolic events
- Headache
- Nausea
- Fatigue
Key clinical trials
- Hydroxyurea and EPO in Sickle Cell Disease (PHASE1, PHASE2)
- Effect of Exercises on Hemodialysis (NA)
- Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (PHASE3)
- Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe) (PHASE2)
- Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants (PHASE3)
- Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants (PHASE3)
- Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia (PHASE2)
- Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- stable erythropoietin therapy CI brief — competitive landscape report
- stable erythropoietin therapy updates RSS · CI watch RSS
- American Regent, Inc. portfolio CI
Frequently asked questions about stable erythropoietin therapy
What is stable erythropoietin therapy?
How does stable erythropoietin therapy work?
What is stable erythropoietin therapy used for?
Who makes stable erythropoietin therapy?
What drug class is stable erythropoietin therapy in?
What development phase is stable erythropoietin therapy in?
What are the side effects of stable erythropoietin therapy?
What does stable erythropoietin therapy target?
Related
- Drug class: All erythropoiesis-stimulating agent drugs
- Target: All drugs targeting erythropoietin receptor
- Manufacturer: American Regent, Inc. — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Anemia associated with chronic kidney disease
- Indication: Drugs for Anemia associated with chemotherapy
- Compare: stable erythropoietin therapy vs similar drugs
- Pricing: stable erythropoietin therapy cost, discount & access